Physician profile
Allison E Doss
NPI 1194148197
$799.50
in general payments reported to CMS, 2019-2025
22 companies · $201 in 2025
The $201 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $80.96 · 2022: $55.18 · 2023: $425 · 2024: $37.72 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $663.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $663.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $199.88 | 2023 | Arexvy, Trelegy Ellipta, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.60 | 2023 | Xifaxan |
| Pfizer INC. | $49.96 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.54 | 2023-2025 | Jardiance |
| Lilly USA, LLC | $40.55 | 2021 | |
| Abbvie INC. | $40.16 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $33.72 | 2023-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Braeburn INC. | $33.10 | 2025 | Brixadi |
| Averitas Pharma INC. | $28.45 | 2025 | Qutenza |
| Novo Nordisk INC | $27.85 | 2022-2023 | Wegovy, Saxenda |
| Baxter Healthcare | $27.22 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Astrazeneca Pharmaceuticals Lp | $27.03 | 2023 | Farxiga |
| Insulet Corporation | $25.16 | 2025 | Omnipod |
| Phathom Pharmaceuticals, INC. | $24.22 | 2024 | Voquezna |
| Novartis Pharmaceuticals Corporation | $21.56 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $18.36 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.23 | 2025 | Caplyta |
| Biohaven Pharmaceuticals, INC. | $17.85 | 2021 | |
| Idorsia Pharmaceuticals US INC | $17.08 | 2022 | |
| Alkermes, INC. | $16.54 | 2025 | Vivitrol |
| Exact Sciences Corporation | $13.50 | 2024 | Cologuard Collection Kit |
| Genentech USA, INC. | $5.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Doss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.